


## XYD198

Cat. No.:	HY-161498
Molecular Formula:	C <sub>54</sub> H <sub>49</sub> F <sub>2</sub> N <sub>11</sub> O <sub>7</sub>
Molecular Weight:	1002.03
Target:	PROTACs; Epigenetic Reader Domain
Pathway:	PROTAC; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC <sub>50</sub> of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499)) <sup>[1]</sup>																
<b>In Vitro</b>	<p>XYD198 (0-1 μM, 72-120 h) inhibits proliferations of acute myeloid leukemia (AML) cells MV4;11, MOLM-13 and MOLM-16, with the IC<sub>50</sub> of 0.9, 47 and 5.5 nM, respectively<sup>[1]</sup>.</p> <p>XYD198 (0-150 nM, 6 h) induces CBP and p300 degradation in bromodomain family proteins in a CRBN- and proteasome-dependent manner<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MV4;11 AML, MOLM-13 and MOLM-16</td> </tr> <tr> <td>Concentration:</td> <td>0-1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>3 days for MOLM-13, 4 days for MV4;11 AML and MOLM-16</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell proliferation.</td> </tr> </table> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MV4;11 AML, MOLM-13 and MOLM-16</td> </tr> <tr> <td>Concentration:</td> <td>0-150 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>6 h</td> </tr> <tr> <td>Result:</td> <td>Degraded CBP and p300 proteins.</td> </tr> </table>	Cell Line:	MV4;11 AML, MOLM-13 and MOLM-16	Concentration:	0-1 μM	Incubation Time:	3 days for MOLM-13, 4 days for MV4;11 AML and MOLM-16	Result:	Inhibited cell proliferation.	Cell Line:	MV4;11 AML, MOLM-13 and MOLM-16	Concentration:	0-150 nM	Incubation Time:	6 h	Result:	Degraded CBP and p300 proteins.
Cell Line:	MV4;11 AML, MOLM-13 and MOLM-16																
Concentration:	0-1 μM																
Incubation Time:	3 days for MOLM-13, 4 days for MV4;11 AML and MOLM-16																
Result:	Inhibited cell proliferation.																
Cell Line:	MV4;11 AML, MOLM-13 and MOLM-16																
Concentration:	0-150 nM																
Incubation Time:	6 h																
Result:	Degraded CBP and p300 proteins.																
<b>In Vivo</b>	<p>CBP/p300 ligand 4 (5 mg/kg, p.o., every other day for 2 weeks) exhibits antitumor activity in MV4;11 xenograft mice model, with a tumor growth inhibition rate TGI of 93%<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																

---

Animal Model:	MV4;11 xenograft NOD-SCID mice model <sup>[1]</sup>
Dosage:	5 mg/kg
Administration:	p.o., every other day for 2 weeks
Result:	Inhibited tumor growth with a TGI of 93%.

---

## REFERENCES

---

[1]. Hu J, et al., Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity. J Med Chem. 2024 May 9;67(9):6952-6986.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA